title: Translational gap in glioma research.
abstract: During the last five decades, enormous advances in treatment modalities for cancer and a better understanding of cancer cell biology have been accomplished but the prognosis of patients carrying malignant gliomas still remains poor despite hundreds of clinical trials have been carried out. In this article we review phase II clinical trials that have been completed and published in PubMed during 2011 in order to investigate potential reasons of clinical failure. We suggest that a translational gap, defined as a failure to translate basic research into clinical trials design may explain the poor outcome of phase II clinical trials.
authors.forename: Chi
authors.initials: C
authors.lastname: Ma
authors.forename: Gang
authors.initials: G
authors.lastname: Zhao
authors.forename: Mabel Hilda
authors.initials: MH
authors.lastname: Cruz
authors.forename: Ake
authors.initials: A
authors.lastname: Siden
authors.affiliation: Department of Clinical Neuroscience, Karolinska University Hospital, Stockholm, Sweden, S-141 86. sebastian.yakisich@ki.se.
authors.forename: Juan Sebastian
authors.initials: JS
authors.lastname: Yakisich
mesh_terms: D001812:Blood-Brain Barrier / Q000378:metabolism; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D017322:Clinical Trials, Phase II as Topic; D005910:Glioma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D057170:Translational Research, Biomedical